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INTRODUCTION
Mucinous ovarian carcinoma is a relatively rare subset of ovarian cancer, accounting for 2-10% of all subtypes of epithelial ovarian cancer (1) (2) . While standard therapy for ovarian cancer includes taxane and platinum-based chemotherapy (3) (4) , such therapy is largely ineffective in patients with mucinous ovarian carcinoma. Consequently, the outcome of women with mucinous ovarian carcinoma is poorer than patients with other epithelial ovarian cancers (5) (6) (7) (8) . Novel therapeutic approaches are urgently needed to improve outcomes of patients with mucinous ovarian carcinoma.
The Src family of non-receptor protein tyrosine kinases (SFKs) regulates various aspects of tumor progression via multiple signaling pathways, including cell survival (PI3K/Akt), growth (Ras/MEK/ERK), metastasis (FAK/paxillin), and angiogenesis (STAT3/VEGF) (9) . Increased Src activity has been demonstrated in colorectal, pancreatic, lung, breast, ovarian, and prostate carcinomas, highlighting Src as a potential therapeutic target (10) (11) . Preclinical data have demonstrated the antitumor activity of Src inhibitors in prostate, colon, and breast cancers (12) (13) (14) . Recently, we reported that Src kinase is overexpressed in mucinous ovarian carcinoma (15) 
In vivo orthotopic model of mucinous ovarian carcinoma
Female athymic nude mice were purchased from the National Cancer Institute- The in vivo model of mucinous ovarian carcinoma (RMUG-S-ip2 and RMUG-L-ip2) used in the present study has been described previously (15) . RMUG-S-ip2 or RMUG-L-ip2 cells were inoculated into the peritoneal cavity of 40 orthotopic nude mice (4×10 6 cells per mouse). Mice were randomized into 4 treatment groups of 10 mice each: control, oxaliplatin, KX-01, and oxaliplatin plus KX-01. Treatments were initiated 4 weeks after
Research. (22) . KX-01 was solubilized in distilled water and administered orally every day (15 mg/kg per mouse, according to the dose finding experiment; see Figure S1A ).
Control mice received HBSS intraperitoneally twice weekly and oral distilled water daily.
Mice were monitored on a daily basis and weighed weekly. After 8 weeks of treatment, the mice were sacrificed and total mouse body weight, tumor location and weight, and number of tumor nodules were recorded. Tumor specimens were preserved in either optimum cutting temperature medium (OCT; Miles Inc., Elkhart, IN; for frozen slides) or fixed in formalin (for paraffin slides) for further analysis.
Reverse phase protein arrays (RPPA)
RMUG-S and RMUG-L cells were treated with KX-01 at a concentration of 100 nM for 24 hours. Cells were homogenized using a digital homogenizer in the following lysis buffer: 1% Triton X-100, 50nM HEPES (pH 7.4), 150mM MgCl 2 , 1mM EGTA, 100mM NaF, 10mM Na-pyrophosphate, 1mM Na 3 VO 4 , 10% glycerol, and freshly added protease and phosphatase inhibitors. Cellular proteins were denatured using 1% sodium dodecyl sulfate (SDS), and five 2× serial dilutions were performed in lysis buffer containing 1% SDS (dilution buffer). These diluted lysates were arrayed on nitrocellulose-coated FAST slides (Whatman Inc., Piscataway, NJ) using an Aushon 2470 Arrayer (Aushon BioSystems, Billerica, MA). Slides were probed with 152 validated primary antibodies and a biotin-conjugated secondary antibody. The Dako Cytomation-catalyzed system (Dako, Carpinteria, CA) was used for signal amplification.
Research. http://bioinformatics.mdanderson.org/OOMPA) was used to generate a fitted curve for each dilution. For both observed and fitted data, the fitted curve was then plotted with the signal intensities on the y-axis and the log 2 concentration of proteins on the x-axis.
From each slide, the protein concentrations were normalized using median polish.
Positive fold-change was calculated by dividing each linear value (>1.0) by the average control linear value for each antibody tested, and negative fold-change (for linear values <1.0) was calculated using the formula (-1/linear fold-change) and plotted in a bar graph.
Western blot analysis
Cell lysates were obtained with RIPA lysis buffer (50mMTris-HCl [pH 7.4], 150mM NaCl, 1% Triton, 0.5% deoxycholate, 25 μg/mL leupeptin, 10 μg/mL aprotinin, 2mM EDTA, and 1mM sodium orthovanadate) and centrifuged for 15 minutes at 4°C. Protein concentration was then determined using the Bio-Rad Protein Assay Kit (Bio-Rad, Hercules, CA). Following protein loading (25μg/well), bands were separated on 8% gel using SDS-PAGE and transferred to nitrocellulose paper, blocked with 5% milk for 1 hour at room temperature, and incubated with primary antibodies overnight at 4°C. The bands were then incubated with horseradish peroxidase-conjugated anti-mouse or anti-
Research. rabbit (GE Healthcare, WI) for 1 hour at room temperature. Blots were developed using an enhanced chemiluminescence detection kit (Pierce Biotechnology, Rockford, IL). β-actin or vinculin was used for loading control, and all experiments were repeated in duplicate. Densitometry (Image J; National Institutes of Health) was used to assess the differences in results.
Cytotoxicity assays
Cells were plated in each well of a 96-well plate and maintained overnight. Cells were then exposed to KX-01 at concentrations of 1nM, 10nM, 100nM, 1000nM, or 10000nM Isobologram analysis was performed to evaluate the cytotoxicity of KX-01 and oxaliplatin in RMUG-S cells using dose-response cell-survival curves (23 interaction index was calculated as described previously (24) . Additive effects (equal to 1), synergistic effects (less than 1), and antagonistic effects (greater than 1) of the combination of oxaliplatin plus KX-01 were determined by the interaction index. Results were evaluated using R (version 2.14.2).
Cell proliferation assays
To determine cell proliferation, we used the Click-iT EdU Flow Cytometry Assay Kit (Invitrogen) according to the manufacturer's protocol. Briefly, cells were incubated with EdU for 2 hours before being harvested, then fixed with Click-iT fixative for 15 minutes at room temperature. After washing was completed, cells were permeabilized with ClickiTsaponin-based permeabilization and wash reagent for 15 minutes, and Click-iT reaction cocktail was added for 30 minutes. Cells were then analyzed using a Beckman Coulter XL 4-color flow cytometer (FACS; Beckman-Coulter, Miami, FL).
Apoptosis and cell cycle assays
Apoptosis was evaluated using the Annexin V-phycoerythrin (PE) apoptosis detection kit (BD Biosciences). Cells were incubated in trypsin-EDTA, and cell pellets were Cells were then assessed for cell cycle status using FACS.
Immunohistochemical and immunofluorescence staining
Immunohistochemical staining was used to detect angiogenesis (CD31), cell proliferation (Ki67), and apoptosis (cleaved caspase-3) in frozen and paraffin-embedded tumor specimens. Paraffin sections were deparaffinized and rehydrated, then antigen retrieval was performed using citrate buffer (pH 6.0). Sections were then blocked with 3% hydrogen peroxide in methanol and 4% fish gelatin at room temperature, then incubated with Ki67 antibody (1:400) overnight at 4°C. After washing with PBS, the sections were incubated with horseradish peroxidase-conjugated rat anti-mouse IgG2a 
PTEN transfection and Src knockdown
For PTEN knock-in experiments, PTEN wild type cDNA was subcloned into the Not I site of a PLNCX expression vector (Clontech Laboratories, Mountain View, CA). PTEN mutants (G129R and PTZB) were generated using a standard mutagenesis method. For retrovirus production, 239T cells were transfected with vector using the calcium
Research. CUGAGAGGGCGGUGGGUAUdTdT; Antisence: UACCCACCGCCCUCUCAGdTdT)
was from Sigma-Aldrich. Transient knockdown experiments with siRNA were performed as described previously (25) .
Statistical analysis

Continuous variables were assessed for normal distribution (Kolmogorov-Smirnov test)
and expressed as appropriate (mean with standard deviation or median with range).
Normally distributed variables were compared using the Student t test (2 groups) or analysis of variance (multiple groups). For variables with nonparametric distribution, the For the RPPA data analysis, to limit the false discovery rate to 5%, each cell line was examined individually. We first completed a 2 × 2 factorial analysis of variance to detect a treatment effect on expression and then used the beta-uniform mixture distribution method (26) to determine a p value cutoff for statistical significance that would limit our false discovery rate to 5%. Finally, if a treatment effect was evident, we tested for
Research. differences between KX-01 and control. After examining each cell line, we used t-tests to determine whether RMUG-S controls differed from RMUG-L controls. We then employed the beta-uniform mixture method again to limit our false discovery rate to 5%.
Linear fold-change was calculated by dividing each linear value by the average control linear value. Positive fold-change (>1.0) was the same as the linear fold-change value; negative fold-change (for linear values <1.0) was calculated as -1/linear fold-change.
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RESULTS
In vivo effects of KX-01 in tumor xenografts
To recapitulate the unique features of mucinous ovarian carcinoma, we have recently established an orthotopic mouse model of metastatic mucinous ovarian carcinoma (15) .The RMUG-S and RMUG-L models were utilized to evaluate the biological effects of KX-01 in vivo. In the RMUG-S model, tumor weight was reduced by 75% (p<0.001) and tumor nodules decreased (p<0.01) following treatment with KX-01 compared with the control group ( Figure 1A ). In the RMUG-L model, tumor weight was reduced by 50% and 48% fewer tumor nodules were observed in the KX-01 treatment group compared with the control group (p<0.05; Figure 1B ).
Because oxaliplatin shows potential as a chemotherapeutic drug for mucinous ovarian carcinoma, we also evaluated the effects KX-01 in combination with oxaliplatin in the RMUG-S and RMUG-L models. In the RMUG-S model, tumor weight was reduced by 90% (p<0.0001) and 85% fewer tumor nodules (p<0.001) were observed in the combination group compared with the control group ( Figure 1A) .Combination therapy led to significantly greater tumor suppression effects than did either monotherapy (combination vs. KX-01, oxaliplatin, 90% vs. 75%, 72%, p<0.05). In the RMUG-L model, while a significant reduction in tumor weight and number of nodules was observed in the combination group compared with the control group, the antitumor effects of the combination therapy did not differ from those of either monotherapy (p>0.05; Figure 1B 
treatment did not differ between the treatment and control groups in either the RMUG-S or RMUG-L model ( Figure S1B , S1C).
To investigate potential mechanisms of KX-01's antitumor activity, we tested markers of cell proliferation (Ki67), angiogenesis (CD31), and apoptosis (cleaved caspase-3) in the tumor tissues. In the RMUG-S model, tumor cell proliferation was reduced in both the KX-01 group (33% reduction, p<0.05) and the oxaliplatin group (29% reduction, p<0.05) compared with the control group. Tumor cell proliferation was most significantly decreased in the combination group compared with the control group (47% reduction, p<0.01; Figure 1C ). Tumor angiogenesis was significantly reduced in all KX-01-based treatment groups compared with the control group (KX-01 vs. control, 43% reduction, p<0.01; combination vs. control, 69% reduction, p<0.0001; Figure 1D ). This difference was not observed in the oxaliplatin group compared with the control group (p>0.05; Figure 1D ).
Tumor cell apoptosis was increased in the oxaliplatin and KX-01 groups compared with the control group (p<0.05; Figure 1E ), with the greatest increase in the combination group (p<0.01; Figure 1E ). In the RMUG-L model, similar biological effects of KX-01 on angiogenesis and cell apoptosis were observed, but the effects of KX-01 on cell proliferation were less pronounced than in the RMUG-S model (21% reduction in RMUG-L vs. 33% reduction in RMUG-S, p<0.01; FigureS2).
In vitro effects of KX-01 in mucinous ovarian carcinoma cells
To identify potential mechanisms by which KX-01 exerts its antitumor activity, we next tested its effects on cell survival, proliferation, apoptosis and migration in mucinous We also tested the effects of various concentrations of combined oxaliplatin and KX-01 in RMUG-S cells. The IC50 of oxaliplatin alone was 14µg/mL; the effects of oxaliplatin, based on increased apoptosis, were significantly enhanced with KX-01 ( Figure 2E, 2F) .
In isobologram analysis, the interaction index was <1 at all examined points, suggesting synergistic effects of oxaliplatin and KX-01 ( Figure 2G ).
Since KX-01 has activity against Src and tubulin, we investigated the effects of a pure Src inhibitor (PP2) or paclitaxel in RMUG-S cells. PP2 had minimal effects on cell survival ( Figure S4A) , and paclitaxel had effects on cell survival at higher concentrations (IC50=147 ng/mL; Figure S4B ). The greater effect observed with KX-01 (Figure 2A paclitaxel with oxaliplatin were also tested, demonstrating that Src siRNA and PP2, but not paclitaxel, resulted in lower IC50 level of oxaliplatin ( Figure S4 C, S4D, S4E) .
Pathways affected by KX-01 treatment in mucinous ovarian carcinoma cells
Because KX-01 was constructed to inhibit phosphorylation of Src substrates, we also tested the effects of KX-01 on Src and FAK, and various Src substrates (Akt, paxillin, and P130cas). In the sensitive RMUG-S cells, expression of p-Akt (ser473), p-paxillin (Tyr118), and p-P130cas (Tyr410) was significantly lower in cells treated with various concentrations of KX-01 for 24 hours than in control cells ( Figure 3A) . In RMUG-L cells, expression of p-paxillin (Tyr118) and p-P130cas (Tyr410) was significantly lower while expression of p-Akt (ser473) was higher in cells treated with KX-01 than in control cells ( Figure 3B ). Expression of p-Src (Tyr416), total-Src, p-FAK (pY397, Tyr576/577, pY861, Tyr925), and total-FAK was not significantly different between the treatment and control cells (data not shown).
The effects of treatment with oxaliplatin alone and the combination of oxaliplatin plus KX-01 on the expression and activation of Src substrates were analyzed in the RMUG-S cell line. Induction of P-Akt, p-paxillin, and p-P130cas activity was seen in the cells in response to oxaliplatin monotherapy, whereas KX-01 blocked oxaliplatin induced p-Akt, p-paxillin, and p-P130cas levels in the cells treated with the combination therapy ( Figure   3C ).
To explore other potential pathways disturbed by KX-01, we utilized RPPAs. This analysis demonstrated that KX-01 inhibited p-Akt (Ser473) expression in RMUG-S cells, but not in RMUG-L cell, consistent with our Western blot results (Table S1, In tumor tissue from orthotopic mouse models, the staining patterns were similar to those of the in vitro tumor cells, and fluorescence intensity was markedly reduced in the KX-01 and combination groups compared with the control group ( Figure 4C, 4D ). In the oxaliplatin group, the staining pattern of tubulin was unchanged from the control group ( Figure 4C, 4D) .
PTEN status affects mucinous ovarian carcinoma cell sensitivity to KX-01
As shown, p-Akt (Ser473) was reduced by KX-01 in the sensitive RMUG-S cells, but not resistance to epidermal growth factor receptor inhibitors (27) (28) , we examined the relationship between PTEN deficiency and response to KX-01 in RMUG-L cells. RMUG-L cells were transfected with wild type or domain mutant (G129R, PTZB) PTEN and then exposed to various concentrations of KX-01 for 72 hours. Sensitivity to KX-01 was significantly enhanced in PTEN-restored cells; IC50 was undetectable in the control cells, but was 464 nM in the PTEN-restored cells. In RMUG-L cells transfected with mutant PTEN, the sensitivity to KX-01 did not differ from that of control cells ( Figure 5A ).
Next, we assessed cell proliferation, apoptosis, and cell cycle status in control, wild type, and PTEN domain mutant RMUG-L cells treated with KX-01. In PTEN wild-type cells, compared with control and domain mutant cells, cell proliferation was significantly inhibited, apoptosis was significantly increased, and the proportion of S phase cells was significantly decreased (Figure 5B, 5C,5D ). In addition, Western blot showed that expression of p-Akt (ser473) and CDC2 was significantly inhibited in PTEN wild-type cells, whereas no change in expression was observed in the control and PTEN domain mutant cells ( Figure 5E ).
Because PTEN is associated with lower levels of p-Akt (29), we also tested both RMUG-S and RMUG-L cells for sensitivity to an Akt1/2 inhibitor. Both RMUG-S and RMUG-L cells were sensitive to the Akt1/2 inhibitor ( Figure S7BD) , and p-Akt expression was significantly decreased in both RMUG-S and RMUG-L cells after treatment with the Akt1/2 inhibitor ( Figure S7C ).
Research. (35) (36) . Recently published data also showed that CDK1 activity promoted cell proliferation and survival and was associated with resistance to therapy (37) , and inhibition of CDK1 was shown to induce cell death and block tumor growth (38) , leading us to suspect that CDK1 may be involved in decreased response to KX-01. The mechanism underling the synergic effect of combination therapy is not completely clear. Our previous data showed that treatment with oxaliplatin alone induced Src kinase activity, which has been proposed as a potential mechanism of resistance to oxaliplatin in mucinous ovarian carcinoma, and that adding the Src/Abl inhibitor dasatinib to the treatment with oxaliplatin could attenuate the oxaliplatin-induced Src kinase activity, leading to synergistic effects (15) . Because induction of Src kinase activity is thought to be associated with drug resistance via the Akt and Ras pathways (22, 43) , our results suggest that KX-01 may inhibit oxaliplatin-induced expression of pAkt, leading to the synergistic effects of the combination therapy.
In summary, our results demonstrate that KX-01 significantly suppresses mucinous ovarian carcinoma by targeting both Src substrates and tubulin. These dual effects may make KX-01 a particularly effective treatment for mucinous ovarian carcinoma. In 
